<DOC>
	<DOCNO>NCT02446249</DOCNO>
	<brief_summary>Background : - Radiation cause parotid salivary gland make less saliva ( dry mouth ) . This cause problem like infection tooth decay . Researchers hope new drug help people dry mouth cause radiation . Objectives : - To examine safety AAV2hAQP1 gene therapy . To see drug increase saliva people whose parotid glands radiation . Eligibility : - People least 18 year age history radiation therapy head neck cancer . Design : - Participants screen 2 visit : - medical history - physical exam - scan - saliva collection - sialogram . A substance inject parotid gland X-rays take . - non-drug infusion - IV dose glycopyrrolate stop saliva - 3-day hospital stay : Participants get gene infusion . The AAV2hAQP1 solution syringe . It slowly push open gland inside mouth.. - 10 outpatient visit 3 year . These may include : - repeat screen test - blood urine test - oral head neck exam , include thin scope airway - questionnaire - small piece skin take - small piece tumor tissue take either : - small video-scope parotid duct also take picture - small needle guide ultrasound - scan . Participants lie machine scanner The machine may feel close body face . . For , substance inject vein put mouth. &lt; TAB &gt; - Participants keep diary feel therapy .</brief_summary>
	<brief_title>Safety Single Administration AAV2hAQP1 , Adeno-Associated Viral Vector Encoding Human Aquaporin-1 One Parotid Salivary Gland People With Irradiation-Induced Parotid Salivary Hypofunction</brief_title>
	<detailed_description>The treatment head neck cancer patient include ionize radiation ( IR ) . Salivary gland IR field suffer irreversible damage . There conventional treatment available correct condition . Our research group develop adeno-associated virus vector base hypothesis vector capable safely transfer human aquaporin-1 ( hAQP1 ) cDNA gene parotid gland adult patient IR-induced salivary hypofunction , result elevate salivary output . Human AQP1 , archetypal water channel , plasma membrane protein facilitate water movement across lipid bilayers . Minipig study show AAV2hAQP1 strategy restore salivary flow IR-damaged salivary gland effective without untoward effect salivary gland delivery . As proof concept AQP1 would restore saliva flow human population , recently complete phase 1 clinical trial ( 06-D-0206 ) use Adenovirus-based vector encode AQP1 single previously irradiate parotid gland eleven patient use open label , single dose , dose-escalation design . All patient tolerate vector delivery study procedure well positive objective subjective response see five patient , dose &lt; 5.8 times10 ( 9 ) vp/gland . At high dos patient possibly initiate immune response vector improvement gland function observe . These finding encourage u pursue study AAV2 base vector , demonstrate low immunogenicity stable expression compare adenoviral vector . The purpose clinical protocol test safety AAV2hAQP1 , measure efficacy , adult patient establish IR-induced parotid gland hypofunction . The targeted tissue site AAV2hAQP1 vector propose study single parotid gland . In Phase 1 dose-escalation study , safety evaluate use conventional clinical immunological parameter . The primary outcome measure biological efficacy parotid gland salivary output .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . At least 18 year age 2 . History radiation therapy head neck cancer , receive &gt; 45Gy parotid gland ( ) use conventional 2D 3D treatment . If radiation therapy give use IMRT , amount radiation receive parotid gland ( ) must exceed 24 Gy . 3 . Abnormal parotid gland function judge absence unstimulated parotid salivary flow stimulate parotid salivary flow target parotid gland &gt; 0 &lt; 0.2 mL/min/gland 2 % citrate stimulation . 4 . No evidence recurrence primary malignancy otolaryngology ( ENT ) assessment . Additionally , patient must diseasefree head neck cancer least 5 year , status determine predose screen use negative clinical exam PET CT image neck chest . 5 . Willingness practice require birth control method ( `` barrier '' contraception , condom , diaphragm ) AAV2hAQP1 longer detectable serum saliva . 6 . Women bear child ( postmenopausal due surgical intervention ) also require practice barrier birth control method AAV2hAQP1 longer detectable serum saliva . 7 . Ability stay NIH hospital period time necessary complete onsite phase protocol ( 35 day ) . 8 . No history allergy medication agent use protocol . 9 . On stable medication ( great equal 2 month ) underlie medical condition time vector administration . EXCLUSION CRITERIA : 1 . Pregnant lactating woman . Women childbearing potential require negative serum pregnancy test screen negative urine pregnancy test within 48 hour prior gene infusion . 2 . Any experimental therapy within 3 month . 3 . Any active respiratory tract infection 3 week prior day 1 protocol 4 . Active infection require use intravenous antibiotic resolve least 1 week Day 1 . 5 . Uncontrolled ischemic heart disease : unstable angina , evidence active ischemic heart disease ECG , congestive heart failure ( left ventricular ejection fraction &lt; 45 % MUGA echo ) cardiomyopathy . 6 . Asthma chronic obstructive pulmonary disease require regular inhaled systemic corticosteroid . 7 . Individuals history autoimmune diseases affect salivary gland , include Sj ( SqrRoot ) ( Delta ) gren syndrome , lupus , scleroderma , type I diabetes , sarcoidosis , amyloidosis , chronic graft versus host disease . 8 . Use systemic immunosuppressive medication ( , i.e. , corticosteroid ) . Topical corticosteroid allow . 9 . Malignancy , head neck , within past 3 year , exception adequately treat basal cell squamous cell carcinoma skin situ cervical carcinoma . 10 . Active infection include EpsteinBarr virus ( EBV ) , cytomegalovirus ( CMV ) , hepatitis B , hepatitis C , human immunodeficiency virus ( HIV ) infection . 11 . WBC &lt; 3000/microL ANC &lt; 1500/microL Hgb &lt; 10.0 g/dL platelet &lt; 100,000/microL absolute lymphocyte count less equal 500/microL . 12 . ALT and/or AST &gt; 1.5 time upper limit normal ( ULN ) alkaline phosphatase &gt; 1.5 time ULN 13 . Serum creatinine &gt; 2 mg/dL . 14 . Serum bilirubin measurement ( total , direct , indirect ) outside normal range . 15 . Individuals active cigarette smoker determine selfreporting . 16 . Individuals allergy iodine shellfish thus unable sialographic evaluation . 17 . Individuals allergy hypersensitivity glycopyrrolate 18 . Individuals whose parotid duct ( ) clinically accessible screen sialography . 19 . Individuals , sialography , distal stenosis would impede vector delivery . 20 . Significant concurrent recently diagnose ( &lt; 2 month ) medical condition , opinion Medically Responsible Investigator , could affect patient 's ability tolerate complete study . 21 . Live vaccine within 4 week first infusion . 22 . Individuals adverse response prednisone ( i.e . hallucination ) . 23 . Individuals uncontrolled diabetes ( HbA1c great 10 % ) . 24 . Individuals untreated severe dental caries , pyorrhea , gingivitis , chronic radiation mucositis ulceration , erythroplasia , leukoplakia premalignant condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 1, 2017</verification_date>
	<keyword>Gene Therapy</keyword>
	<keyword>Xerostomia</keyword>
</DOC>